CPRiL

5 Functional Relationships(s) Download
	Sentence	Compound Name	Protein Name	Organism
1	Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report.	osimertinib	epidermal growth factor receptor	Homo sapiens
2	Although clinical trials of AURA series illustrated that non-small cell lung cancer (NSCLC) with EGFR T790M mutation can benefit from osimertinib, only five LSCC patients were enrolled in total; moreover, the efficacy for LSCC was not shown in the results.	osimertinib	epidermal growth factor receptor	Homo sapiens
3	CASE SUMMARY: We report an LSCC case with T790M-related acquired resistance after treatments with first-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs) and benefited from osimertinib significantly.	osimertinib	epidermal growth factor receptor	Homo sapiens
4	CASE SUMMARY: We report an LSCC case with T790M-related acquired resistance after treatments with first-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs) and benefited from osimertinib significantly.	osimertinib	epidermal growth factor receptor	Homo sapiens
5	CONCLUSION: Our findings highlight that EGFR T790M mutation may also be an important acquired drug resistance mechanism for LSCC and offer direct evidence of the efficacy of osimertinib in LSCC with T790M mutation.	osimertinib	epidermal growth factor receptor	Homo sapiens